<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity</h2>
    <div class="badge">2025-09-08T15:00:00+00:00</div>
    <ul>
      <li>2021 Jan 14;7(1):3.</li>
<li>Sci Rep 15, 23495 (2025).</li>
<li>2014 Oct 21;121(5):664–672.</li>
<li>Food and Drug Administration (“FDA”) for the treatment of patients with small cell lung cancer in 2025.</li>
<li>The 5-year survival rate for patients with extensive-stage SCLC is only 5%, emphasizing the need for new treatment options that extend progression-free survival.2, 3 About pumitamig (also known as BNT327 or BMS986545) Pu</li>
<li>About Small Cell Lung Cancer Small cell lung cancer (SCLC) accounts for 15% of all lung cancer cases, with an estimated 250,000 new cases globally per year.1 It is the most aggressive type of lung cancer often spreading</li>
<li>doi: 10.1038/s41572-020-00235-0.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity\n• 2021 Jan 14;7(1):3.\n• Sci Rep 15, 23495 (2025).\n• 2014 Oct 21;121(5):664–672.\n• Food and Drug Administration (“FDA”) for the treatment of patients with small cell lung cancer in 2025.\n• The 5-year survival rate for patients with extensive-stage SCLC is only 5%, emphasizing the need for new treatment options that extend progression-free survival.2, 3 About pumitamig (also known as BNT327 or BMS986545) Pu\n• About Small Cell Lung Cancer Small cell lung cancer (SCLC) accounts for 15% of all lung cancer cases, with an estimated 250,000 new cases globally per year.1 It is the most aggressive type of lung cancer often spreading\n• doi: 10.1038/s41572-020-00235-0." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/first-disclosure-global-interim-phase-150000388.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>